Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 47

1.

Quantitative Genetics Validates Previous Genetic Variants and Identifies Novel Genetic Players Influencing Alzheimer's Disease Cerebrospinal Fluid Biomarkers.

de Matos MR, Ferreira C, Herukka SK, Soininen H, Janeiro A, Santana I, Baldeiras I, Almeida MR, Lleó A, Dols-Icardo O, Alcolea D, Benussi L, Binetti G, Paterlini A, Ghidoni R, Nacmias B, Meulenbroek O, van Waalwijk van Doorn LJC, Kuiperij HB, Hausner L, Waldemar G, Simonsen AH, Tsolaki M, Gkatzima O, de Oliveira CR, Verbeek MM, Clarimon J, Hiltunen M, de Mendonça A, Martins M.

J Alzheimers Dis. 2018 Oct 9. doi: 10.3233/JAD-180512. [Epub ahead of print]

PMID:
30320580
2.

Plasma Aβ (Amyloid-β) Levels and Severity and Progression of Small Vessel Disease.

van Leijsen EMC, Kuiperij HB, Kersten I, Bergkamp MI, van Uden IWM, Vanderstichele H, Stoops E, Claassen JAHR, van Dijk EJ, de Leeuw FE, Verbeek MM.

Stroke. 2018 Apr;49(4):884-890. doi: 10.1161/STROKEAHA.117.019810. Epub 2018 Mar 14.

PMID:
29540613
3.

Biomarkers in cerebrospinal fluid for synucleinopathies, tauopathies, and other neurodegenerative disorders.

Marques TM, Van Rumund A, Kuiperij HB, Verbeek MM.

Handb Clin Neurol. 2017;146:99-113. doi: 10.1016/B978-0-12-804279-3.00007-1. Review.

PMID:
29110782
4.

Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: An update of the Consensus of the Task Force on Biological Markers in Psychiatry of the World Federation of Societies of Biological Psychiatry.

Lewczuk P, Riederer P, O'Bryant SE, Verbeek MM, Dubois B, Visser PJ, Jellinger KA, Engelborghs S, Ramirez A, Parnetti L, Jack CR Jr, Teunissen CE, Hampel H, Lleó A, Jessen F, Glodzik L, de Leon MJ, Fagan AM, Molinuevo JL, Jansen WJ, Winblad B, Shaw LM, Andreasson U, Otto M, Mollenhauer B, Wiltfang J, Turner MR, Zerr I, Handels R, Thompson AG, Johansson G, Ermann N, Trojanowski JQ, Karaca I, Wagner H, Oeckl P, van Waalwijk van Doorn L, Bjerke M, Kapogiannis D, Kuiperij HB, Farotti L, Li Y, Gordon BA, Epelbaum S, Vos SJB, Klijn CJM, Van Nostrand WE, Minguillon C, Schmitz M, Gallo C, Lopez Mato A, Thibaut F, Lista S, Alcolea D, Zetterberg H, Blennow K, Kornhuber J; Members of the WFSBP Task Force Working on this Topic: Peter Riederer, Carla Gallo, Dimitrios Kapogiannis, Andrea Lopez Mato, Florence Thibaut.

World J Biol Psychiatry. 2018 Jun;19(4):244-328. doi: 10.1080/15622975.2017.1375556. Epub 2017 Oct 27. Review.

PMID:
29076399
5.

Multicenter Analytical Validation of Aβ40 Immunoassays.

van Waalwijk van Doorn LJC, Kulic L, Koel-Simmelink MJA, Kuiperij HB, Versleijen AAM, Struyfs H, Twaalfhoven HAM, Fourier A, Engelborghs S, Perret-Liaudet A, Lehmann S, Verbeek MM, Vanmechelen EJM, Teunissen CE.

Front Neurol. 2017 Jul 3;8:310. doi: 10.3389/fneur.2017.00310. eCollection 2017.

6.

Improved Cerebrospinal Fluid-Based Discrimination between Alzheimer's Disease Patients and Controls after Correction for Ventricular Volumes.

van Waalwijk van Doorn LJ, Gispert JD, Kuiperij HB, Claassen JA, Arighi A, Baldeiras I, Blennow K, Bozzali M, Castelo-Branco M, Cavedo E, Emek-Savaş DD, Eren E, Eusebi P, Farotti L, Fenoglio C, Ormaechea JF, Freund-Levi Y, Frisoni GB, Galimberti D, Genc S, Greco V, Hampel H, Herukka SK, Liu Y, Lladó A, Lleó A, Nobili FM, Oguz KK, Parnetti L, Pereira J, Picco A, Pikkarainen M, de Oliveira CR, Saka E, Salvadori N, Sanchez-Valle R, Santana I, Scarpini E, Scheltens P, Soininen H, Tarducci R, Teunissen C, Tsolaki M, Urbani A, Vilaplana E, Visser PJ, Wallin AK, Yener G, Molinuevo JL, Meulenbroek O, Verbeek MM.

J Alzheimers Dis. 2017;56(2):543-555. doi: 10.3233/JAD-160668.

PMID:
28059783
7.

MicroRNAs in Cerebrospinal Fluid as Potential Biomarkers for Parkinson's Disease and Multiple System Atrophy.

Marques TM, Kuiperij HB, Bruinsma IB, van Rumund A, Aerts MB, Esselink RAJ, Bloem BR, Verbeek MM.

Mol Neurobiol. 2017 Dec;54(10):7736-7745. doi: 10.1007/s12035-016-0253-0. Epub 2016 Nov 14.

8.

Limitations of the hCMEC/D3 cell line as a model for Aβ clearance by the human blood-brain barrier.

Biemans EALM, Jäkel L, de Waal RMW, Kuiperij HB, Verbeek MM.

J Neurosci Res. 2017 Jul;95(7):1513-1522. doi: 10.1002/jnr.23964. Epub 2016 Oct 11.

9.

Tau Rather than TDP-43 Proteins are Potential Cerebrospinal Fluid Biomarkers for Frontotemporal Lobar Degeneration Subtypes: A Pilot Study.

Kuiperij HB, Versleijen AA, Beenes M, Verwey NA, Benussi L, Paterlini A, Binetti G, Teunissen CE, Raaphorst J, Schelhaas HJ, Küsters B, Pijnenburg YA, Ghidoni R, Verbeek MM.

J Alzheimers Dis. 2017;55(2):585-595.

PMID:
27662293
10.

CSF d-serine concentrations are similar in Alzheimer's disease, other dementias, and elderly controls.

Biemans EA, Verhoeven-Duif NM, Gerrits J, Claassen JA, Kuiperij HB, Verbeek MM.

Neurobiol Aging. 2016 Jun;42:213-6. doi: 10.1016/j.neurobiolaging.2016.03.017. Epub 2016 Mar 23.

PMID:
27143438
11.

Validation of microRNAs in Cerebrospinal Fluid as Biomarkers for Different Forms of Dementia in a Multicenter Study.

Müller M, Kuiperij HB, Versleijen AA, Chiasserini D, Farotti L, Baschieri F, Parnetti L, Struyfs H, De Roeck N, Luyckx J, Engelborghs S, Claassen JA, Verbeek MM.

J Alzheimers Dis. 2016 Apr 16;52(4):1321-33. doi: 10.3233/JAD-160038.

PMID:
27104900
12.

Validation of soluble amyloid-β precursor protein assays as diagnostic CSF biomarkers for neurodegenerative diseases.

van Waalwijk van Doorn LJ, Koel-Simmelink MJ, Haußmann U, Klafki H, Struyfs H, Linning P, Knölker HJ, Twaalfhoven H, Kuiperij HB, Engelborghs S, Scheltens P, Verbeek MM, Vanmechelen E, Wiltfang J, Teunissen CE.

J Neurochem. 2016 Apr;137(1):112-21. doi: 10.1111/jnc.13527. Epub 2016 Jan 24.

13.

A multifunctional ELISA to measure oxidised proteins: oxPin1 in Alzheimer's brain as an example.

Herbert MK, Verbeek MM, Küsters B, Kuiperij HB.

BBA Clin. 2015 Apr 30;4:1-6. eCollection 2015 Dec.

14.

A Practical Guide to Immunoassay Method Validation.

Andreasson U, Perret-Liaudet A, van Waalwijk van Doorn LJ, Blennow K, Chiasserini D, Engelborghs S, Fladby T, Genc S, Kruse N, Kuiperij HB, Kulic L, Lewczuk P, Mollenhauer B, Mroczko B, Parnetti L, Vanmechelen E, Verbeek MM, Winblad B, Zetterberg H, Koel-Simmelink M, Teunissen CE.

Front Neurol. 2015 Aug 19;6:179. doi: 10.3389/fneur.2015.00179. eCollection 2015.

15.

The utility of α-synuclein as biofluid marker in neurodegenerative diseases: a systematic review of the literature.

Simonsen AH, Kuiperij B, El-Agnaf OM, Engelborghs S, Herukka SK, Parnetti L, Rektorova I, Vanmechelen E, Kapaki E, Verbeek M, Mollenhauer B.

Biomark Med. 2016;10(1):19-34. doi: 10.2217/BMM.14.105. Epub 2015 Aug 28. Review.

PMID:
26314196
16.

Dickkopf-related protein 3 is a potential Aβ-associated protein in Alzheimer's Disease.

Bruggink KA, Kuiperij HB, Gloerich J, Otte-Höller I, Rozemuller AJ, Claassen JA, Küsters B, Verbeek MM.

J Neurochem. 2015 Sep;134(6):1152-62. doi: 10.1111/jnc.13216. Epub 2015 Jul 16.

17.

Validation of a quantitative cerebrospinal fluid alpha-synuclein assay in a European-wide interlaboratory study.

Kruse N, Persson S, Alcolea D, Bahl JM, Baldeiras I, Capello E, Chiasserini D, Bocchio Chiavetto L, Emersic A, Engelborghs S, Eren E, Fladby T, Frisoni G, García-Ayllón MS, Genc S, Gkatzima O, Heegaard NH, Janeiro AM, Kováčech B, Kuiperij HB, Leitão MJ, Lleó A, Martins M, Matos M, Mollergard HM, Nobili F, Öhrfelt A, Parnetti L, de Oliveira CR, Rot U, Sáez-Valero J, Struyfs H, Tanassi JT, Taylor P, Tsolaki M, Vanmechelen E, Verbeek MM, Zilka N, Blennow K, Zetterberg H, Mollenhauer B.

Neurobiol Aging. 2015 Sep;36(9):2587-96. doi: 10.1016/j.neurobiolaging.2015.05.003. Epub 2015 May 15.

PMID:
26093515
18.

CSF Neurofilament Light Chain but not FLT3 Ligand Discriminates Parkinsonian Disorders.

Herbert MK, Aerts MB, Beenes M, Norgren N, Esselink RA, Bloem BR, Kuiperij HB, Verbeek MM.

Front Neurol. 2015 May 5;6:91. doi: 10.3389/fneur.2015.00091. eCollection 2015.

19.

MicroRNA-29a Is a Candidate Biomarker for Alzheimer's Disease in Cell-Free Cerebrospinal Fluid.

Müller M, Jäkel L, Bruinsma IB, Claassen JA, Kuiperij HB, Verbeek MM.

Mol Neurobiol. 2016 Jul;53(5):2894-2899. doi: 10.1007/s12035-015-9156-8. Epub 2015 Apr 21.

20.

Cerebrospinal Fluid NrCAM is not a Suitable Biomarker to Discriminate between Dementia Disorders--A Pilot Study.

Müller M, Claassen JA, Kuiperij HB, Verbeek MM.

J Alzheimers Dis. 2015;46(3):605-9. doi: 10.3233/JAD-142901.

PMID:
25812850

Supplemental Content

Loading ...
Support Center